Back to Search
Start Over
Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database
- Source :
- Rheumatology, Rheumatology, Oxford University Press (OUP), 2021, 60 (3), pp.1243-1251. ⟨10.1093/rheumatology/keaa448⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- Objective PsA is a chronic inflammatory arthritis with heterogeneous disease manifestations. Data on the prevalence of PsA in adults differ widely depending on the study and the country. This study aimed to estimate the prevalence and incidence of PsA in France, characterize comorbidities associated to PsA and identify prescribed treatments. Methods This nationwide cohort study involved the administrative healthcare database (Système National des Données de Santé) of the French health insurance scheme linked to the national hospital discharge database. All adults with PsA registered in the database and identified with a specific International Classification of Diseases, 10th revision code (M07) were included between 1 January 2015 and 31 December 2018. Results A total of 63 598 patients were identified as having PsA [55.9 years (s.d. 14.4), 45.6% males]. The prevalence of PsA was estimated at 0.1% and the incidence at 8.4 per 100 000 person-years in the general population. The most common comorbidities were hypertension, diabetes, chronic obstructive pulmonary disease and dyslipidaemia. The prevalence of treatment with conventional synthetic DMARDs (csDMARDs), biological or biosimilar DMARDs (b/bsDMARDs) and apremilast for PsA was 25.9% (16 453), 30.4% (19 325) and 3.5% (2231), respectively. Overall, 8966 (14.1%) patients were new users of csDMARDs, 8311 (13.1%) were new users of b/bsDMARDs and 1529 (7.4%) were new users of apremilast. The most common first-line csDMARD was methotrexate (70.9%) and the most frequent first-line b/bsDMARD was adalimumab (30.8%). Conclusion Our results lead to a better understanding of PsA. Results were similar to those from other published studies using other data sources, which highlights the reliability of insurance databases for studies.
- Subjects :
- Male
medicine.medical_specialty
Databases, Factual
Population
Comorbidity
Cohort Studies
Pulmonary Disease, Chronic Obstructive
03 medical and health sciences
Psoriatic arthritis
0302 clinical medicine
Rheumatology
Internal medicine
Epidemiology
Diabetes Mellitus
Prevalence
medicine
Adalimumab
Humans
Pharmacology (medical)
030212 general & internal medicine
education
Biosimilar Pharmaceuticals
Dyslipidemias
030203 arthritis & rheumatology
Biological Products
education.field_of_study
business.industry
Incidence
Incidence (epidemiology)
Arthritis, Psoriatic
Middle Aged
medicine.disease
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Antirheumatic Agents
Hypertension
Female
France
Apremilast
business
Cohort study
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 14620324 and 14602172
- Database :
- OpenAIRE
- Journal :
- Rheumatology, Rheumatology, Oxford University Press (OUP), 2021, 60 (3), pp.1243-1251. ⟨10.1093/rheumatology/keaa448⟩
- Accession number :
- edsair.doi.dedup.....3ec63b7462f7757db29a7a028c8afda0